Peginterferon Alfa-2a and Ribavirin for 16 or 24 Weeks in HCV Genotype 2 or 3

In patients with chronic hepatitis C virus genotype 2 or 3 participating in this randomized trial, the sustained virologic response rate was higher with 24 weeks of peginterferon and ribavirin than with 16 weeks of treatment (70% vs. 62%, P

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2007-07, Vol.357 (2), p.124-134
Hauptverfasser:	Shiffman, Mitchell L, Suter, Fredy, Bacon, Bruce R, Nelson, David, Harley, Hugh, Solá, Ricard, Shafran, Stephen D, Barange, Karl, Lin, Amy, Soman, Ash, Zeuzem, Stefan
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Anemia - chemically induced Antibiotics. Antiinfectious agents. Antiparasitic agents Antiviral agents Antiviral Agents - administration & dosage Antiviral Agents - adverse effects Biological and medical sciences Drug Administration Schedule Drug therapy Drug Therapy, Combination Female General aspects Genotype Genotype & phenotype Hepacivirus - genetics Hepatitis Hepatitis C - drug therapy Hepatitis C - virology Hepatitis C virus Humans Interferon-alpha - administration & dosage Interferon-alpha - adverse effects Male Medical sciences Middle Aged Neutropenia - chemically induced Patients Pharmacology. Drug treatments Polyethylene Glycols - administration & dosage Polyethylene Glycols - adverse effects Recombinant Proteins Ribavirin - administration & dosage Ribavirin - adverse effects RNA, Viral - blood Viral Load
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In patients with chronic hepatitis C virus genotype 2 or 3 participating in this randomized trial, the sustained virologic response rate was higher with 24 weeks of peginterferon and ribavirin than with 16 weeks of treatment (70% vs. 62%, P
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa066403